17
Views
5
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Outcome of patients with rheumatoid arthritis treated by step-wise administration of disease-modifying antirheumatic drugs over a 10-year period

, , &
Pages 27-34 | Received 05 Nov 2001, Accepted 05 Jun 2002, Published online: 02 Jan 2014

References

  • Shinomiya F, Hamada Y. Outcome of step-wise use of DMARDs in patients with early rheumatoid arthritis. Clinical efficacy of DMARD therapy in delaying the progression of multiple joint destruction (in Japanese). Igaku no Ayumi 1998;186:149–53.
  • Shinomiya F, Hamada Y. Long-term results of DMARDs use (in Japanese). In: Nishioka K, Nakamura H, editors. DMARDs use manual for the practice of medicine. Tokyo: Medical Pharmaco-logical Journal; 2001. p. 117–34.
  • Lockie M, Smith DM. Forty-seven years experience with gold therapy in 1019 rheumatoid arthritis patients. Sem Arthritis Rheum 1985;14:238.
  • Baum J.Continuing look at penicillamine. J Ftheumato11979;6:3–6.
  • Shinomiya F, Okada M, Kanazawa K, Hamada Y, Ooishi T. Efficacy of auranofin administration for patients with early rheu-matoid arthritis (in Japanese). Med Consult New Rem 1992;29: 14. 1419–29.
  • Furst DE. Clinical pharmacology of combination DMARD therapy in rheumatoid arthritis. J Ftheumatol 1996;23:86–90.
  • Lansbury J. Report of three-year study on the systematic and 15. articular indexes in rheumatoid arthritis. Arthritis Rheum 1958;1:505-22.16.
  • Fries CF. Reevaluating the therapeutic approach to rheumatoid arthritis: the sawtooth strategy. J Ftheumatol 1990;17 Supp1:12–5.
  • Searle G, McKendry RJR. Methotrexate pneumonitis in rheuma- 17. toid arthritis. J Ftheumatol 1987;14:1164–71.
  • Rosenthal M. Loss of efficacy of anti-rheumatic drugs in rheuma-toid arthritis. J Ftheumatol 1980;7:586–91.
  • Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U, 18. et al. Patients with rheumatoid arthritis benefit from early second-line therapy: 5-year follow up of a prospective double- 19. blind placebo-controlled study. J Ftheumatol 1995;22: 2208–13.
  • Yamamoto S, Nakata S, Takubo N. Can DMARDs prevent articu- 20. lar destruction in RA? J Orthop Ftheumatol 1996;9: 52–7.
  • Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Gold-smith C, et al. American College of Rheumatology preliminarydefinition of improvement in rheumatoid arthritis. ArthritisRheum 1995;38:727�35.
  • Sharp JT, Young DY, Gluhm GB, Brook A, Brower AC, Corbett M, et al. How many joints in the hands and wrists should be included in a score of radiological abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 1985;28:1326�35.
  • Masi AT, Feigenbaum SL, Kaplan SB. Articular patterns in the early course of rheumatoid arthritis. Am J Med 1983;30:16�26.
  • Welsing PMJ,Gestel AM,Swinkels HL,Kiemeney LALM,Riel PLCM. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis. Rheum 2001;44:2009�17.
  • Ochi T, Iwase R, Yonemasu K, Matsukawa M, Yoneda M, Yukioka M, et al. Natural course of joint destruction and fluctuation of serum C1q levels in patients with rheumatoid arthritis. Arthritis Rheum 1988;31:37�43.
  • Wilske KR, Healey LA. Remodeling the pyramid: a concept whose time has come. J Rheumatol 1989;19:565�7.
  • Wilske KR. Remodeling the therapeutic pyramid: evolving therapeutic strategies for rheumatoid arthritis. Jpn J Rheumatol 1999;9:1�16.
  • Shinomiya F, Okada M, Kanazawa K, Ooishi T, Hamada Y, Araki M. Clinical courses and prognosis of multiple artificial joint replacement for patients with mutilating rheumatoid arthritis(in Japanese). Orthop Surg 1992;43:319�27.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.